Increase of number of shares and votes in Vicore Pharma

Gothenburg, June 30, 2022– Vicore Pharma Holding AB (publ)’s registered share capital and number of outstanding shares and votes have increased during the month of June 2022.

As previously announced, the Company’s board of directors resolved on a set-off issue of 87,686 shares at a subscription price of SEK 34.21 per share on June 17, 2022. The set-off issue was carried out as part of a milestone payment to the company's collaboration partners Emeriti Bio AB and HaLaCore Pharma AB, for the start of a phase 1 trial with C106.

As of today, the total number of registered and outstanding shares and votes of Vicore Pharma amounts to 71,847,979. Furthermore, the registered share capital amounts to approximately SEK 35,923,989.15.

For further information, please contact:

Carl-Johan Dalsgaard, CEO, tel: +46 70 975 98 63, carl-johan.dalsgaard@vicorepharma.com  

Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

This information is information that Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on June 30, 2022, at 09:00 CEST.

About Vicore Pharma Holding AB (publ)

Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe diseases where the Angiotensin II type 2 receptor (AT2R) plays an important role. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary artery hypertension (PAH) and COVID-19. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.